O'Reilly RA, Aggeler PM, Hoag MS, et al. Hereditary transmission of exceptional resistance to
coumarin anticoagulant drugs: the first reported kindred.
N Engl J Med.1964;271:809-815.
3.
O'Reilly RAThe second reported kindred with hereditary resistance to oral
anticoagulant drugs. N Engl J Med.1970;282:1448-1454.
4.
Freeman BD, Zehnbauer BA, McGrath S., Borecki I., Buchman TGCytochrome P450 polymorphisms are associated with reduced warfarin
dose. Surgery.
2000;128:281-285.
5.
Meyer UAPharmacogenetics and adverse drug reactions.
Lancet.
2000;356:1667-1671.
6.
Rost S., Fregin A., Ivaskevicius V., et al. Mutations in VKORC1 cause warfarin resistance and
multiple coagulation factor deficiency type 2.
Nature.
2004;427:537-541.
7.
Li T., Chang CY, Jin DY, et al. Identification of the gene for vitamin K epoxide
reductase. Nature.
2004;427:541-544.
8.
D'Andrea G., D'Ambrosio RL, Di Perna P., et al. A polymorphism in the VKORC1 gene is associated with
an interindividual variability in the dose-anticoagulant effect of
warfarin. Blood.2005;105:645-649.
9.
Margaglione M., Colaizzo D., D'Andrea G., et al. Genetic modulation of oral anticoagulation with
warfarin. Thromb Haemost.2000;84:775-778.
10.
D'Andrea G. , D'Ambrosio RL, Di Perna P., et al. A polymorphism in the VKORC1 gene is associated with
an interindividual variability in the dose-anticoagulant effect of
warfarin. Blood.2005;105:645-649.
